DF
SAGE

Donoghue Forlines’s Sage Therapeutics SAGE Stock Holding History

Donoghue Forlines’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,780
Closed -$272K – 239
2021
Q2 		$272K Buy
4,780
+705
+17% +$49.8K 0.05% 198
2021
Q1 		$305K Buy
+4,075
New +$334K 0.06% 205

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Donoghue Forlines's SAGE Position: Q3 2021 in Review

Donoghue Forlines sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 4,780 shares — an estimated $272K sold.

Donoghue Forlines first reported a position in SAGE in Q1 2021 and held it in 2 quarters. The position peaked at $305K in Q1 2021. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Donoghue Forlines reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Donoghue Forlines sold 4,780 Sage Therapeutics shares in Q3 2021, an estimated $272K.
  • Donoghue Forlines first reported a position in Sage Therapeutics in Q1 2021 and held it in 2 quarters.
  • Donoghue Forlines's Sage Therapeutics position peaked at $305K in Q1 2021.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Donoghue Forlines's 13F filing for Q3 2021, filed 15 Nov 2021.